Last updated: July 30, 2026
Purdue Pharma v. Alvogen Pine Brook LLC (1:15-cv-00687): Litigation Summary, Patent Scope, and Exclusivity Impact
Purdue Pharma L.P. sued Alvogen Pine Brook LLC in E.D. Texas over prescription opioid product IP under a federal patent case filed April 2015. The docket is 1:15-cv-00687 and is tied to Purdue’s broader strategy to stop generic or authorized-generic entry for a branded opioid while enforcing Orange Book-linked patent rights and related patent claims.
What is the Purdue Pharma v. Alvogen Pine Brook LLC case 1:15-cv-00687 about?
Featured-snippet answer: The case is a patent infringement dispute brought by Purdue Pharma L.P. against Alvogen Pine Brook LLC in U.S. District Court for the Eastern District of Texas (E.D. Texas) under docket 1:15-cv-00687.
Core claim theme
- Purdue alleged Alvogen’s product would infringe Purdue patents covering an approved branded opioid and related protected aspects (typically one or more of: composition/formulation, method of use, or manufacturing/encapsulation).
- The posture is consistent with an Orange Book / Hatch-Waxman enforcement framework: Purdue’s suit is commonly used to block a generic launch during the pendency of patent validity and infringement determinations.
Court and procedural posture
- Venue: E.D. Texas
- Case number: 1:15-cv-00687
- Filing year: 2015
(Source: docket identifier supplied in the request.)
Which patents were asserted in Purdue Pharma L.P. v. Alvogen Pine Brook LLC?
Featured-snippet answer: The asserted patent set and claim numbers are not determinable from the information provided in the prompt.
Why patent identification matters
In opioid Orange Book litigations, the asserted patents determine:
- Whether the suit targets formulation/composition versus method of use
- Whether Purdue seeks injunctive relief that can trigger carve-outs or stipulated non-infringement
- Whether the case can pivot to validity issues (obviousness, indefiniteness, anticipation)
What to map in an enforceability/strategy analysis
For an accurate litigation analysis, you typically build a matrix of:
- Patent number(s)
- Expiration date(s)
- Type: composition, formulation, method of use, packaging, or manufacturing
- Claim limitations relevant to Alvogen’s proposed product
- Ownership/assignee chain and licensing posture (Purdue vs. subsidiary holders)
What happened procedurally in the case (motions, Markman, stays, and final outcomes)?
Featured-snippet answer: Procedural outcomes are not determinable from the information provided in the prompt.
Common procedural outcomes in this fact pattern
Opioid brand-generic patent cases in this period often end in one of:
- Consent judgment or stipulation after a narrowing claim construction
- Dismissal for lack of infringement or withdrawal of asserted claims
- Settlement with a launch date date and/or covenant-not-to-sue
- Summary judgment or trial with an appellate track
Key docket events analysts track
- Claim construction (Markman) orders
- DAubert rulings on expert testimony
- Summary judgment milestones
- Settlement docket entries and dismissal terms
- Any Federal Circuit appeal and mandate
Did the case involve a Paragraph IV certification or a Hatch-Waxman dispute?
Featured-snippet answer: The case ID suggests a Hatch-Waxman enforcement suit, but the specific certification type (Paragraph IV, carve-out, Paragraph III, or no certification) is not determinable from the prompt.
What “Paragraph IV” usually implies
If Purdue sued after receiving a generic application notice alleging non-infringement and/or invalidity:
- The case can trigger a statutory 30-month stay of FDA approval
- The litigation timing often aligns with FDA milestones and FDA approval dates
When does the asserted patent estate expire and how does that affect generic entry?
Featured-snippet answer: Patent expiration dates cannot be provided without the asserted patent numbers.
What expiration mapping requires
To model generic entry risk, the analysis must include:
- Each asserted patent’s listed expiration
- Any extended exclusivity (e.g., pediatric exclusivity) if applicable
- Whether earlier expirations create “at-risk” launch pathways
What did Purdue demand and what relief did it seek?
Featured-snippet answer: The complaint’s specific requested relief is not determinable from the information provided in the prompt.
Typical relief in this category of case
- Permanent injunction against infringement
- Monetary damages (to the extent allowed)
- Attorney fees in exceptional cases
- Declaratory judgment on infringement/validity
How strong is Purdue’s patent position versus Alvogen’s invalidity arguments?
Featured-snippet answer: The strength of Purdue’s estate and the merits of Alvogen’s defenses cannot be assessed without the asserted patents, claim construction, and dispositive rulings.
Defense vectors to evaluate in opioid formulation cases
- Anticipation by prior art references (including earlier dosage forms and release profiles)
- Obviousness under §103
- Indefiniteness under §112
- Prosecution history estoppel and claim scope limitations
- Non-infringement based on process parameters (particle size, release kinetics, excipient selection)
What settlement terms are typical in Purdue-type opioid patent suits involving Alvogen?
Featured-snippet answer: Settlement terms are not determinable from the information provided in the prompt.
Settlement term types analysts see
- Dismissal with prejudice conditioned on payment or ongoing royalties
- Launch date restrictions (time-based)
- Covenant-not-to-sue for certain SKUs
- Carve-out: design changes to avoid infringement
- License structure with territory and duration controls
How does this lawsuit connect to FDA regulatory status and Orange Book listings?
Featured-snippet answer: Orange Book linkage and FDA pathway details are not determinable from the information provided in the prompt.
What to verify for a full regulatory linkage analysis
- FDA product reference (listed drug)
- Which patents are listed for that NDA/ANDA
- Which patents correspond to the asserted patents
- Whether the generic entry was blocked or enabled by settlement
Which products were at issue: what drug and dosage form did Alvogen seek to launch?
Featured-snippet answer: The specific Alvogen product and dosage form are not determinable from the information provided in the prompt.
Why product identity is essential
In opioid litigation, infringement often turns on:
- Release mechanism (immediate vs. extended release)
- Dosage strength and dosing regimen
- Formulation constraints (matrix vs. coating, antagonist combinations, excipient profiles)
- Manufacturing process and bioequivalence design
How does Purdue’s Alvogen litigation compare with other brand-generic opioid cases?
Featured-snippet answer: Comparative conclusions cannot be stated without asserted patents, outcomes, and the specific Alvogen product.
What “comparison” typically covers
- Speed to resolution (weeks vs. months vs. years)
- Whether courts reached merits or disposed on procedural grounds
- Whether Markman narrowed claims materially
- Whether injunction was granted or settlement substituted for adjudication
- Whether there were parallel district-court and Federal Circuit steps
Revenue and commercialization impact: what risk does this case create for Alvogen and for Purdue?
Featured-snippet answer: Revenue exposure cannot be quantified from the prompt.
What the case usually impacts
- Generic launch timing for the infringing SKU
- Potential loss of exclusivity for Purdue if patents fall
- Potential settlement value and royalty considerations for Purdue
Key timelines you must extract from the docket to finalize a litigation assessment
Featured-snippet answer: Specific docket timestamps are not provided in the prompt.
Minimum timeline set
- Complaint filing date
- Service and first responsive filing
- Claim construction scheduling order and Markman date
- Summary judgment deadlines
- Trial date (if any)
- Dispositive outcome date
- Dismissal/settlement filing date
Key Takeaways
- Purdue Pharma L.P. v. Alvogen Pine Brook LLC (E.D. Texas, 1:15-cv-00687) is a brand-versus-generic patent infringement enforcement matter in 2015 tied to Purdue’s IP relating to a marketed opioid.
- The prompt does not include the asserted patent numbers, procedural outcomes, or FDA/Orange Book linkage, so a complete litigation merits and exclusivity analysis cannot be made from the provided data.
FAQs
- What court handled Purdue Pharma v. Alvogen Pine Brook LLC under docket 1:15-cv-00687?
- What patents were asserted in 1:15-cv-00687 and what claim types did Purdue target?
- Was the case resolved by trial, summary judgment, or settlement?
- Does 1:15-cv-00687 relate to a specific Orange Book-listed patent for a Purdue opioid?
- What generic launch date or injunction outcome flowed from Purdue’s suit?
References
- Federal docket identifier provided in prompt: Purdue Pharma L.P. v. Alvogen Pine Brook LLC, 1:15-cv-00687 (E.D. Texas).
